MIOMIE: Morbidity in Open Versus Minimally Invasive Esophagectomy

Sponsor
Austrian Society Of Surgical Oncology (Other)
Overall Status
Completed
CT.gov ID
NCT03035071
Collaborator
(none)
26
2
71.6

Study Details

Study Description

Brief Summary

The MIOMIE trial is a prospective randomized controlled study comparing open and laparoscopic gastric tube formation in Ivor Lewis esophagectomy. Aim of this trial was to compare the minimally invasive approach with the standard open procedure regarding morbidity and mortality.

Condition or Disease Intervention/Treatment Phase
  • Procedure: minimally invasive esophagectomy
  • Procedure: open esophagectomy
N/A

Detailed Description

Esophageal resection is still associated with considerable morbidity and mortality. Standardized preoperative efforts could increase the outcome of these patients. While early reports of medical pioneers focused particularly on safety and feasibility, more recent studies showed that implementation of minimally invasive esophagectomy (MIE) was widely accepted. Since first reports of MIE, different techniques and adjustments have been discussed. A recent publication of a large prospective trial in Phase II showed the safety of a total minimally invasive approach (video assisted thoracoscopic surgery (VATS) and laparoscopy). Surgical technique however is still a subject of debate and the level of evidence remains still low. Proving feasibility does not warrant a paradigm shift, as experience is an important factor for safety and patient benefit.

The aim of this study was to evaluate morbidity and mortality of open esophagectomy (OE) versus hybrid-MIE in a randomized controlled setting.

Prior to surgery patients will be randomized either the minimally invasive surgery group (laparoscopic gastric tube formation and thoracotomy) or the the open surgery group (open gastric tube formation with an open laparotomy approach). Randomizing tool is the "randomizer" of the medical university of vienna. (link is attached below)

Study Design

Study Type:
Interventional
Actual Enrollment :
26 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy
Actual Study Start Date :
May 1, 2010
Actual Primary Completion Date :
Nov 19, 2014
Actual Study Completion Date :
Apr 18, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: minimally invasive esophagectomy

minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.

Procedure: minimally invasive esophagectomy
In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.

Active Comparator: open esophagectomy

open gastric mobilization and gastric tube formation

Procedure: open esophagectomy
in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.

Outcome Measures

Primary Outcome Measures

  1. morbidity [30 days]

    anastomotic leakage, gastric conduit necrosis and/or pneumonia

  2. mortality [30 days]

Secondary Outcome Measures

  1. ICU stay [90 days]

    length of stay at the intensive care unit (ICU)

  2. hospital stay [90 days]

    length of stay at the hospital

  3. overall survival [5 years]

    long term overall survival

  4. relapse free survival [5 years]

    long term relapse free survival

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • adenocarcinoma of the esophagus and the esophagogastric junction in (Siewert) type I and II position

  • esophageal squamous cell cancer

  • patients, who require esophageal resection due to above mentioned diagnosis

  • patients, who gave their informed consent

Exclusion Criteria:
  • individuals who did not meet the inclusion criteria were excluded from the study.

  • patients with tumor localization in the upper third of the esophagus and requiring cervical resection were excluded.

  • patients, presenting other than AC or ESCC or showed contraindication for laparoscopy (history of large abdominal surgery or signs of hostile abdomen)

  • patients with a history or presence of any other malignancy, except carcinoma in situ or basalioma

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Austrian Society Of Surgical Oncology

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Matthias Paireder, MD, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT03035071
Other Study ID Numbers:
  • AUT-MIOMIE-RCT
First Posted:
Jan 27, 2017
Last Update Posted:
Jan 27, 2017
Last Verified:
Jan 1, 2017
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Matthias Paireder, MD, Medical University of Vienna

Study Results

No Results Posted as of Jan 27, 2017